@article{oai:repo.qst.go.jp:00046677,
 author = {Okada, Tomoko and Murata, Kazuhiro and Hirose, Ryoma and Matsuda, Chie and Komatsu, Tsunehiko and Ikekita, Masahiko and Nakawatari, Miyako and Nakayama, Fumiaki and Wakatsuki, Masaru and Ohno, Tatsuya and Kato, Shingo and Imai, Takashi and Imamura, Toru and 松田 知栄 and 中渡 美也子 and 中山 文明 and 若月 優 and 加藤 眞吾 and 今井 高志},
 issue = {2899},
 journal = {Scientific Reports (Online Only URL:http://www.nature.com/srep/index.html)},
 month = {Oct},
 note = {Cancer cells often develop drug resistance. In cisplatin-resistant HeLa cisRcells, fibroblast growth factor 13 (FGF13/FHF2) gene and protein expression was strongly upregulated, and intracellular platinum concentrations were kept low. When the FGF13 expression was suppressed, both the cells' resistance to platinum drugs and their ability to keep intracellular platinum low were abolished. Overexpression of FGF13 in parent cells led to greater resistance to cisplatin and reductions in the intracellular platinum concentration. These cisplatin-resistant cells also showed increased resistance to copper. In preoperative cervical cancer biopsy samples from poor prognoses patients after cisplatin chemoradiotherapy, FGF13-positive cells were detected more abundantly than in the biopsy samples from patients with good prognoses. These results suggest that FGF13 plays a pivotal role in mediating resistance to platinum drugs, possibly via a mechanism shared by platinum and copper. Our results point to FGF13 as a novel target and useful prognostic guide for cancer therapy.},
 title = {Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells},
 volume = {3},
 year = {2013}
}